Abstract _ Full Text (HTML) _ Full Text (PDF)

Research Article

Cancer Research Frontiers. 2015 Sep; 1(3): 288-298. doi: 10.17980/2015.288

Clinical Relevance of Viable Circulating Tumor Cells detected by PSA-EPISPOT prior Trans-rectal Prostate Biopsy

Thibaut Murez1, Xavier Rebillard2, Rodolphe Thuret1, Laure Cayrefourcq 3,4, Bruno Segui2, Antoine Faix2, Samer Abdel-Hamid2, Carine Plassot4, Catherine Alix-Panabières3,4[*]

 

1Urology and Kidney grafting Department, Montpellier University Medical Centre – Lapeyronie Hospital, 371 avenue du doyen Gaston Giraud, 34295 Montpellier Cedex 5, France

2Urology Department, Beausoleil Clinic, 119 avenue de Lodève, 34070 Montpellier, France

3Cell and Tissue Biopathology of tumors Department, University Medical Centre – Saint-Eloi Hospital, Laboratory of Rare Human Circulating Cells, Montpellier, France

4University Institute of Clinical Research, University Montpellier – EA2415 – Help for Personalized Decision: Methodological Aspects, 641 avenue du doyen Gaston Giraud, 34093 Montpellier Cedex 5, France

 

[*]Corresponding author: Catherine Alix-Panabières, Laboratory of Rare Human Circulating Cells (LCCRH), Department of Cellular & Tissular Biopathology of Tumors, University Institute of Clinical Research (IURC), 641, avenue du Doyen Gaston Giraud, 34093 Montpellier Cedex 5, France, e-mail: c-panabieres@chu-montpellier.fr; Tél +33 (0)4 11 75 99 31, Fax +33 (0)4 11 75 99 33.

Citation: Thibaut Murez, et al. Clinical Relevance of Viable Circulating Tumor Cells detected by PSA-EPISPOT prior Trans-rectal Prostate Biopsy. Cancer Research Frontiers. 2015 Sep; 1(3): 288-298. doi: 10.17980/2015.288

Copyright: @ 2015 Thibaut Murez, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing Interests: The authors declare that there are no competing interests.

Received October 5, 2015; Revised December 14, 2015; Accepted December 18, 2015. Published December 23, 2015

 

Abstract

Background: Accurate new tools are advocated to help clinical decisions from screening to follow-up and salvage-treatment of prostate cancer. We report here the clinical relevance of the PSA-EPISPOT assay for circulating tumor cells (CTCs) detection prior to immediate prostate biopsy.

Patients and Methods: One hundred and eleven patients selected to undergo prostate biopsy based on conventional triggering markers were recruited between 2002 and 2006. CTCs in the peripheral blood were detected by the fluoroPSA-EPISPOT assay. Peripheral blood was sampled before prostate biopsy. CTC enumeration was performed with an EpCAM-independent enrichment method followed by the fluoroPSA-EPISPOT assay that detects only viable PSA-secreting CTCs.

Results: Sixty-three patients were negative biopsy and 48 were positive. Median follow-up was 69.5 months [0.8 – 115.8]. Viable CTCs were detected in 12/63 negative biopsy patients (19%) and 23/48 positive biopsy patients (47.9%). CTC mean count was significantly higher in positive biopsy patients (2 ± 3.1) than in negative biopsy patients (0.7 ± 1.9; p=0.0015). PSA-EPISPOT characteristics were respectively 47.92%, 80.95%, 65.71%, 67.11%, 66.67% for sensitivity, specificity, positive and negative predictive value and accuracy. PSA-EPISPOT was better than random to predict positive biopsy but not different from total PSA. Its relation to other markers made the PSA-EPISPOT assay not eligible to multivariate logistic regression.

Conclusion: This report indicates that PSA-EPISPOT technique was able to detect CTCs in patients screened for prostate cancer. Despite interesting characteristics, it was not sensitive enough to prevent each unnecessary prostate biopsy. Further analyses are mandatory to assess the prognosis value of the PSA-EPISPOT assay in positive biopsy patients.

Keywords: circulating tumor cell, prostate cancer, screening, biomarker, diagnosis

 

 

 

 

 

 

 

 

 

 

 

Multiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier SchönmannMultiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier Schönmann